title: [A survival of 103 cases of T-cell non-Hodgkin lymphoma].
abstract: OBJECTIVE
  T-cell non-Hodgkin lymphoma was heterogeneous and relatively high incident in our country. It's response and prognosis were poor. This study was to analyze clinical feature and survival of T-NHL.
  
  
  METHODS
  Records of 103 cases with T-NHL, treated from Dec 1998 to Dec 2004 in Cancer Center of Sun Yat-sen University, were retrospectively analyzed. All the patients were classified according to WHO 2001 Classification Criteria.
  
  
  RESULTS
  Median age of the whole group was 35 (ranged 2-78) years-old. Of the 103 cases, 68 were male, 35 were female; 25 (24.3%) received chemoradiotherapy, 70 (68.0%) received chemotherapy alone, 3 received radiotherapy and 5 received stem cell transplantation after complete remission. Median survival was 24.1 (ranged 0.8-84) months. 5-year survival rate was 24.3%. Kaplan-Meier analysis discovered that age > 60 years, advanced stage (stage II, IV), extranodal involvement, bulky disease, B symptom, performance status (PS) > or = 2, LDH elevated, hypoalbumin, median-high IPI (IPI > or = 2) were bad to prognosis, but Cox regression found that age > or = 60 years, performance status (PS) > or = 2S, hypoalbumin were the independent bad factors to prognosis.
  
  
  CONCLUSIONS
  This study proved that age, albumin, PS were the independent factors to prognosis.
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
authors.forename: Yan-Xia
authors.initials: YX
authors.lastname: Shi
authors.forename: Rou-Jun
authors.initials: RJ
authors.lastname: Peng
authors.forename: Su-Xia
authors.initials: SX
authors.lastname: Lin
authors.forename: Qiu-Liang
authors.initials: QL
authors.lastname: Wu
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Sun
authors.forename: Hui-Qiang
authors.initials: HQ
authors.lastname: Huang
authors.forename: Zhong-Jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Dong-Geng
authors.initials: DG
authors.lastname: Liu
authors.forename: Zhong-Zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004358:Drug Therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D016896:Treatment Outcome